BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19015637)

  • 1. PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage.
    Gresko E; Ritterhoff S; Sevilla-Perez J; Roscic A; Fröbius K; Kotevic I; Vichalkovski A; Hess D; Hemmings BA; Schmitz ML
    Oncogene; 2009 Feb; 28(5):698-708. PubMed ID: 19015637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
    Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
    Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PML-RARα and its phosphorylation regulate pml oligomerization and HIPK2 stability.
    Shima Y; Honma Y; Kitabayashi I
    Cancer Res; 2013 Jul; 73(14):4278-88. PubMed ID: 23722549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.
    Möller A; Sirma H; Hofmann TG; Rueffer S; Klimczak E; Dröge W; Will H; Schmitz ML
    Cancer Res; 2003 Aug; 63(15):4310-4. PubMed ID: 12907596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.
    Hofmann TG; Möller A; Sirma H; Zentgraf H; Taya Y; Dröge W; Will H; Schmitz ML
    Nat Cell Biol; 2002 Jan; 4(1):1-10. PubMed ID: 11740489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of component exchange at PML nuclear bodies.
    Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
    J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.
    D'Orazi G; Cecchinelli B; Bruno T; Manni I; Higashimoto Y; Saito S; Gostissa M; Coen S; Marchetti A; Del Sal G; Piaggio G; Fanciulli M; Appella E; Soddu S
    Nat Cell Biol; 2002 Jan; 4(1):11-9. PubMed ID: 11780126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
    Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
    J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.
    Shima Y; Shima T; Chiba T; Irimura T; Pandolfi PP; Kitabayashi I
    Mol Cell Biol; 2008 Dec; 28(23):7126-38. PubMed ID: 18809579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
    Reuven N; Adler J; Porat Z; Polonio-Vallon T; Hofmann TG; Shaul Y
    J Biol Chem; 2015 Jul; 290(27):16478-88. PubMed ID: 25944899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
    Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
    Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR.
    Winter M; Sombroek D; Dauth I; Moehlenbrink J; Scheuermann K; Crone J; Hofmann TG
    Nat Cell Biol; 2008 Jul; 10(7):812-24. PubMed ID: 18536714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.
    Engelhardt OG; Boutell C; Orr A; Ullrich E; Haller O; Everett RD
    Exp Cell Res; 2003 Feb; 283(1):36-50. PubMed ID: 12565818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
    Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
    Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
    Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
    Di Stefano V; Soddu S; Sacchi A; D'Orazi G
    Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
    Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
    Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.
    Perfettini JL; Nardacci R; Séror C; Bourouba M; Subra F; Gros L; Manic G; Amendola A; Masdehors P; Rosselli F; Ojcius DM; Auclair C; de Thé H; Gougeon ML; Piacentini M; Kroemer G
    Cell Death Differ; 2009 Feb; 16(2):298-311. PubMed ID: 19023333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPK2 restricts SIRT1 activity upon severe DNA damage by a phosphorylation-controlled mechanism.
    Conrad E; Polonio-Vallon T; Meister M; Matt S; Bitomsky N; Herbel C; Liebl M; Greiner V; Kriznik B; Schumacher S; Krieghoff-Henning E; Hofmann TG
    Cell Death Differ; 2016 Jan; 23(1):110-22. PubMed ID: 26113041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
    Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
    Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.